GL1X · GenesisL1 explorer

MolNFT v1 · #104159 · protein

Crystal structure of the plectin 1 and 2 repeats of the human periplakin. northeast structural genomics consortium (nesg) target HR9083A

4Q28: “Crystal structure of the plectin 1 and 2 repeats of the human periplakin. northeast structural genomics…”. X-ray diffraction, 11 pockets (best druggability 0.52). MolNFT v1 #104159 on GenesisL1: 3D structure, binding sites and…

PDB
4Q28
Type
protein
Length
438 residues
Chains
4
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Periplakin
UniProt
O60437
Pockets
11 · best druggability 0.52

Structure

x-ray diffraction · 2 distinct chains · 33% helix, 33% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, BPeriplakinprotein11033% helix, 33% strandO60437
C, DPeriplakinprotein10934% helix, 34% strandO60437

Pockets

11 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
1940.520.8420empty
2550.500.8716empty
31540.460.7722empty
4630.450.8317empty
5930.430.7919empty

Interfaces

5 interfaces between chains.

  • A–D · 1235 Ų buried · 21 hydrogen bonds · protein-protein
  • B–C · 1173 Ų buried · 19 hydrogen bonds · protein-protein
  • A–B · 911 Ų buried · 11 hydrogen bonds · protein-protein
  • B–D · 141 Ų buried · 1 hydrogen bond · protein-protein
  • A–C · 130 Ų buried · 0 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 12 modified (engineered).

Compared structures

  • 4Q28 · Crystal Structure of the Plectin 1 and 2 Repeats of the Human Periplakin. Northeast… · the same entry in another collection · chain A against A, TM-score 1.00
  • O60437 · AlphaFold monomer V2.0 prediction for periplakin (O60437) · a predicted model of the same protein · chain A against A, TM-score 0.80

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.